Franklin Genomic AdvancementHELXETF
13F holders, Q1 2025 (March 31)8holders
2new positions
2sold out
1famous investor
$27.00avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings, unchanged from Q4 2024. 2 opened new positions and 2 sold out. The largest holders were Citadel Advisors ($1.2M), LPL Financial LLC ($482K) and Jane Street Group, LLC ($217K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $71K |
| Exits | 2 | $953K |
All 13F filers, Q4 2024 → Q1 2025: 44,653 shares bought and 66,006 shares sold, net −21,353 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Citadel Advisors | 0.00% | Add +478.9% | 46,119 | $1.2M |
| LPL Financial LLC | 0.00% | Add +5.2% | 17,850 | $482K |
| Jane Street Group, LLC | 0.00% | Reduce -80.4% | 8,049 | $217K |
| UBS Group AG | 0.00% | Add +25.7% | 2,661 | $72K |
| Osaic Holdings, Inc. | 0.00% | New | 2,630 | $71K |
| Halbert Hargrove Global Advisors, LLC | 0.00% | Add +41.8% | 2,554 | $69K |
| Harbour Investments, Inc. | 0.00% | Add +1240.4% | 1,823 | $49K |
| Morgan Stanley | 0.00% | New | 1 | $33 |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.